A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Brian A. Gordon et al.|Nature Medicine|2021Cited by 365
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s diseaseErik C. B. Johnson, Yudy Milena Leon, Shijia Bian et al.|Nature Medicine|2023Cited by 172
CSF proteomics identifies early changes in autosomal dominant Alzheimer’s diseaseYuanyuan Shen, Jigyasha Timsina, Gyujin Heo et al.|Cell|2024Cited by 60
Amyloid‐Related Imaging Abnormalities in the <scp>DIAN‐TU</scp>‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph‐Mathurin, Richard J. Perrin, Jorge J. Llibre‐Guerra et al.|Annals of Neurology|2022Cited by 42
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Yan Li et al.|The Lancet Neurology|2025Cited by 39